Baseline Factors Associated with Improvements in Decompensated Cirrhosis After Direct-acting Antiviral Therapy for HCV Infection

Hepatitis

Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study

Lancet Gastroenterol Hepatol.

Feld JJ, Cypel M, Kumar D, Dahari H, Pinto Ribeiro RV, Marks N, Kamkar N, Bahinskaya I, Onofrio FQ, Zahoor MA, Cerrochi O, Tinckam K, Kim SJ, Schiff J, Reichman TW, McDonald M, Alba C, Waddell TK, Sapisochin G, Selzner M, Keshavjee S, Janssen HLA, Hansen BE, Singer LG, Humar A

doi: 10.1016/S2468-1253(20)30081-9.

Gastrointestinal Cancer

Direct-Acting Antiviral Therapy for HCV Infection is Associated with Increased Survival in Patients With a History of Hepatocellular Carcinoma

Gastroenterology.

Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC

doi: 10.1053/j.gastro.2019.07.040.

Hepatitis

Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study

Lancet Gastroenterol Hepatol.

Bethea ED, Gaj K, Gustafson JL, Axtell A, Lebeis T, Schoenike M, Turvey K, Coglianese E, Thomas S, Newton-Cheh C, Ibrahim N, Carlson W, Ho JE, Shah R, Nayor M, Gift T, Shao S, Dugal A, Markmann J, Elias N, Yeh H, Andersson K, Pratt D, Bhan I, Safa K, Fishman J, Kotton C, Myoung P, Villavicencio MA, D'Alessandro D, Chung RT, Lewis GD

doi: 10.1016/S2468-1253(19)30240-7.

HepatitisHepatology

Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study

Gut.

Hutchinson SJ, Valerio H, McDonald SA, Yeung A, Pollock K, Smith S, Barclay S, Dillon JF, Fox R, Bramley P, Fraser A, Kennedy N, Gunson RN, Templeton K, Innes H, McLeod A, Weir A, Hayes PC, Goldberg D

doi: 10.1136/gutjnl-2019-320007.

Hepatitis

Patient-reported symptoms during and after direct acting antiviral therapies for chronic hepatitis C: The PROP UP Study

J Hepatol.

Evon DM, Sarkar S, Amador J, Lok AS, Sterling RK, Stewart PW, Reeve BB, Serper M, Reau N, Rajender Reddy K, Di Bisceglie AM, Nelson DR, Golin CE, Lim JK, Fried MW

doi: 10.1016/j.jhep.2019.04.016.

Hepatitis

Identification of Micro RNA Associated with the Elimination of Hepatitis C Virus Genotype 1b by Direct-Acting Antivirals Therapies

J Gastroenterol Hepatol

Yoneyama H, Morishita A, Iwama H, Fujita K, Masaki T, Tani J, Tadokoro T, Nomura T, Sakamoto T, Oura K, Takuma K, Nakahara M, Mimura S, Deguchi A, Oryu M, Tsutsui K, Himoto T, Shimotohno K, Wakita T, Kobara H, Masaki T

doi: 10.1111/jgh.15224

Hepatitis

Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-acting Antiviral Agents

Clin Gastroenterol Hepatol.

Mendizabal M, Piñero F, Ridruejo E, Wolff FH, Anders M, Reggiardo V, Ameigeiras B, Palazzo A, Alonso C, Schinoni MI, Videla Zuain MG, Tanno F, Figueroa S, Santos L, Peralta M, Soza A, Vistarini C, Adrover R, Fernández N, Perez D, Hernández N, Estepo C, Bruno A, Descalzi V, Sixto M, Borzi S, Cocozzella D, Zerega A, de Araujo A, Varón A, Rubinstein F, Cheinquer H, Silva M

doi: 10.1016/j.cgh.2020.02.044.

Hepatitis

Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension

J Hepatol.

Lens S, Baiges A, Alvarado E, LLop E, Martinez J, Fortea JI, Ibañez L, Mariño Z, Rodríguez-Tajes S, Gallego A, Bañares R, Puente Á, Albillos A, Calleja JL, Torras X, Hernández-Gea V, Bosch J, Villanueva C, García-Pagán JC, Forns X

doi: 10.1016/j.jhep.2020.05.050.

HepatitisHepatology

Sustained virologic response by direct-acting antivirals suppresses skeletal muscle loss in hepatitis C virus infection

J Gastroenterol Hepatol.

Endo K, Sato T, Suzuki A, Yoshida Y, Kakisaka K, Miyasaka A, Takikawa Y

doi: 10.1111/jgh.14991.

Related content

Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study

Direct-Acting Antiviral Therapy for HCV Infection is Associated with Increased Survival in Patients With a History of Hepatocellular Carcinoma

Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study

Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study

Patient-reported symptoms during and after direct acting antiviral therapies for chronic hepatitis C: The PROP UP Study

Identification of Micro RNA Associated with the Elimination of Hepatitis C Virus Genotype 1b by Direct-Acting Antivirals Therapies

Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-acting Antiviral Agents

Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension

Sustained virologic response by direct-acting antivirals suppresses skeletal muscle loss in hepatitis C virus infection